Product Overview

In the rapidly evolving field of mRNA therapeutics and vaccines, accurate characterization of poly(A) tail length has become a critical quality control step. Hzymes’ mRNA poly(A) Tail Length Test Sample Preprocessing Kit offers a fast, reproducible, and LC-MS compatible solution for mRNA tail length analysis — delivering results in just 1 hour.

Why Poly(A) Tail Length Matters in mRNA Drug Development

The poly(A) tail is a stretch of adenine nucleotides added to the 3′ end of mRNA molecules. Its length directly influences mRNA stability, translation efficiency, and overall therapeutic performance.

In mRNA vaccines, such as those used for infectious diseases and cancer immunotherapy, poly(A) tail length is recognized as a critical quality attribute (CQA) by global regulatory guidelines, including the USP Draft Guidance for mRNA Vaccine Quality Analysis Methods. Ensuring the right poly(A) tail length is essential for:

• Maintaining mRNA integrity during manufacturing and storage
• Optimizing protein expression in the target cells
• Achieving consistent therapeutic efficacy and safety

Figure 1. mRNA Drug substance characterization and release testing in the USP mRNA Vaccine Quality Analysis Methods-Draft Guidelines

Hzymes’ Solution:

Simple to operate and effort saving

the kit operation is simple and fast; the whole process can be completed within 1hour.

Reliable Preprocessing

The system was systematically optimized with high recovery rate.

Compatible with downstream LC-MS

Combined with LC-S analysis, it can stably and accurately detect the poly(A)tail length distribution of mRNA 3'end.

Super Stability

RNase T1 Mix within the kit is still efficient for digestion even after 37℃ thermal acceleration for 10 days or freezing and thawing for10 times.

Product Performance

Sample Pre-processing

Incubate 100pmol of mRNA at 95 '℃ for 5min and then quickly cool down to 25 ℃; Add RNase T1 digestion mix and incubated for 15min at room temperature; After digestion, perform purification with oligo dT binding. The optimized purification and elution system can stably recover the mRNA 3'end poly (A) tail fragment, which is ready for LC-MS analysis. The whole process can be completed within 1 hour.

LC-MS analysis

The treated samples were subjected to LC-Ms determination to analyze the poly (A) tail length distribution. Theretention time of target component 30A was 3.25min and 70A was 3.58min in sample 1. The TlC profiles are shown in Figure 2, and the deconvolved molecular weight maps of sample 1 at different retention times are shown in Figure 3.4.MS result matched the targets in sample 1, and the Ms matching table is shown in Table 1-2.

Figure 2. The TlC profile was detected by LC-MS of sample 1. Sample 1was analyzed by liquid mass to isolated two peaks.

Figure 3. The TlC profile was detected by LC-MS of sample 1. Different amounts of PolyA were identified after deconvolution result analysis of the peaks with 3.25min retention time. Based on the molecular weight results, the PolyA distribution of sample 1 is 29A-34A, which matches the theoretical sequence.

Figure 4. The TlC profile was detected by LC-MS of sample 1 Sample 1retention time 3.58min deconvoluted the molecular weight map. Different amounts of PolyA were identified after deconvolution result analysis of the peaks with 3.58min retention time. Based on the molecular weight results, the polyA distribution of sample 1 was63A-81A corresponding to the theoretical sequence.

Table 1. Nucleotide sequence matching of target component 30A of sample 1 and PolyA length distribution

Table 2. Nucleotide sequence matching of sample 1 target component 70A and PolyA length distribution

Applications

• mRNA Vaccine Development – Ensure compliance with quality attributes
• mRNA Therapeutics QC – For cancer, infectious disease, and rare genetic disorders
• Process Development & GMP Release – Robust for both R&D and manufacturing

Ordering